Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung City, Taiwan; Department of Public Health, Chung Shan Medical University, Taichung City, Taiwan.
Department of Public Health, Chung Shan Medical University, Taichung City, Taiwan; Department of Occupational Health Nursing Center, Chung Shan Medical University Hospital, Taichung City, Taiwan.
Diabetes Metab. 2024 Jul;50(4):101546. doi: 10.1016/j.diabet.2024.101546. Epub 2024 Jun 5.
The influence of menopausal hormone therapy (MHT) on the probability of developing diabetes mellitus in individuals with prediabetes remains uncertain.
This retrospective cohort study, utilizing the TriNetX U.S. Collaborative Network, investigated cohorts, implemented propensity score matching, and analyzed outcomes associated with diabetes mellitus. The study focused on individuals aged 46-60 with prediabetes prior to menopause, categorizing them into MHT and non-MHT groups. Further stratified analyses, including variables such as age and race, were conducted to thoroughly examine potential variations in outcomes.
The study involved 6566 individuals (MHT and non-MHT), with propensity score matching ensuring balanced cohorts. Over a 20-year follow-up, the MHT group demonstrated a lower incidence of diabetes mellitus compared to the non- MHT group, with a Hazard Ratio of 0.693 (95 % CI: 0.577, 0.832). Stratified analyses revealed age-specific nuances, with significant protective effects in individuals aged 46-50 and 55-60. Additionally, ethnicity played a role, with MHT demonstrating significant benefits in White individuals but not in the Black or Asian populations. BMI analysis indicated a significant risk reduction with MHT in individuals with BMI less than or equal to 24.9 and 25-29.9 kg/m , but not in those with BMI greater than or equal to 30 kg/m .
In our study, we demonstrate a sustained 20-year decrease in the risk of diabetes among premenopausal individuals with prediabetes who undergo menopausal hormone therapy.
围绝经期激素治疗（MHT）对糖尿病前期个体发生糖尿病的概率的影响仍不确定。
本回顾性队列研究利用 TriNetX 美国合作网络，调查队列，实施倾向评分匹配，并分析与糖尿病相关的结局。研究对象为绝经前患有糖尿病前期的 46-60 岁个体，将其分为 MHT 和非 MHT 组。进一步进行分层分析，包括年龄和种族等变量，以全面检查结局的潜在变化。
该研究共纳入 6566 名个体（MHT 和非 MHT），通过倾向评分匹配确保了均衡的队列。在 20 年的随访期间，MHT 组发生糖尿病的发生率低于非 MHT 组，风险比为 0.693（95%CI：0.577，0.832）。分层分析显示年龄具有特异性，46-50 岁和 55-60 岁的个体有显著的保护作用。此外，种族也起作用，MHT 在白种人中具有显著益处，但在黑人和亚洲人群中则没有。BMI 分析表明，在 BMI 小于或等于 24.9 和 25-29.9 kg/m 的个体中，MHT 可显著降低风险，但在 BMI 大于或等于 30 kg/m 的个体中则没有。
在我们的研究中，我们表明绝经前患有糖尿病前期的个体接受激素治疗后，糖尿病的风险在 20 年内持续降低。
